University of Calgary
UofC Navigation


tempo logo web

   TEMPO-1 – TNK-tPA evaluation for minor ischemic stroke with proven occlusion

Thrombolysis for minor ischemic stroke with proven acute symptomatic occlusion using TNK-tPA



Patients with TIA or minor ischemic stroke are generally not considered candidates for acute thrombolysis because they are judged to be too mild to warrant thrombolytic treatment.  Up to a third of these patients, however, deteriorate and end up disabled.  The recent CATCH study, which enrolled patients with TIA or minor ischemic stroke (NIHSS <=3) showed that patients with an acute intracranial occlusion were the most likely to deteriorate.

TNK-tPA (tenecteplase) is a novel plasminogen activator in widespread use for the treatment of myocardial infarction.  It has pharmacologic properties, such as increased fibrin specificity and long half life, that may make lower doses at prolonged time windows safe for use in ischemic stroke.


Trial Design

TEMPO-1 is a dose-escalation safety study.  Two dose tiers at 0.1mg/kg and 0.25mg/kg will be completed sequentially.  All patients will be treated within 90 minutes of CT angiogram.  Patients will have a baseline NIHSS score <= 5 and have proven intra-cranial arterial occlusion.  The primary outcome is safety and secondary outcomes are for efficacy.



The trial will be conducted in sites in Canada only.

Media Coverage

Dr. Shelagh Coutts discusses the results of the TEMPO-1 Trial at the 2015 International Stroke Conference in Nashville, TN. 



Michael D Hill, Shelagh B Coutts – Principal Investigators

Carol Kenney – Nurse Coordinator

Michelle Wright – Financial and Contracts Coordinator

For more information please email or call 1-855-4TEMPO1 (1-855-483-6761)